Ashish Gupta, MD
Cardiovascular Disease · Phoenix, AZNPI 1982782470
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $786,311 of the $1,078,862 with a category attached, or 72.9%. 56 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 44.1% of the total. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,373 payments — averaging $454.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$475K
- Bayer$202K
- Boston Scientific$178K
- Impulse Dynamics (USA) Inc.$84K
- Merck$67K
- Abbott$21K
- plus $52K from 50 others
Across 25 payments — averaging $3648.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$36K
- Impulse Dynamics (USA) Inc.$34K
- Actelion Pharmaceuticals, Ltd$20K
- Actelion Pharmaceuticals US, Inc.$2K
What the payments were for
- Consulting fees$36,9373%
- Speaking & faculty fees$786,31173%
- Travel & lodging$159,99815%
- Food & beverage$94,8939%
- Education$7240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$415,251
- OPSUMIT$370,704
- Adempas$176,996
- OPTIMIZER$156,143
- WATCHMAN Access System$113,524
- WINREVAIR$59,221
- Watchman$52,723
- Barostim Neo System$10,442
- CARDIOMEMS$8,537
- Indigo System$4,546
- WATCHMAN FLX$4,260
- CardioMEMS HF System$3,410
- ORENITRAM$3,347
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$3,273
- GENERAL - THERAPIES$2,449
- FLOWTRIEVER CATHETER, S$2,075
- Confirm Rx$1,872
- ATRICLIP LAA EXCLUSION SYSTEM$1,031
- OPTIMIZER SMART SYSTEM$985
- 3F$976
How this compares
$1,078,862 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 214 | $2,840,455 |
| OpsumitMacitentan | 222 | $2,775,901 |
| UptraviSelexipag | 101 | $2,395,799 |
| EliquisApixaban | 498 | $553,957 |
| EntrestoSacubitril/Valsartan | 111 | $135,682 |
| Repatha SureclickEvolocumab | 150 | $130,032 |
| XareltoRivaroxaban | 127 | $113,695 |
| BrilintaTicagrelor | 63 | $58,412 |
| Metoprolol Succinate | 1,196 | $20,054 |
| Praluent PenAlirocumab | 33 | $16,297 |
| VascepaIcosapent Ethyl | 16 | $8,263 |
| Atorvastatin Calcium | 558 | $5,685 |
| Ezetimibe | 182 | $4,583 |
| Amlodipine Besylate | 677 | $4,296 |
| Losartan Potassium | 356 | $4,127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $475,242 | $5,171,700323 claims |
| BayerAdempas | $202,056 | $2,840,455214 claims |
| PfizerEliquis | $250 | $553,957498 claims |
| NovartisEntresto | $1,562 | $135,682111 claims |
| Johnson & JohnsonXarelto | $685 | $113,695127 claims |
| AstraZenecaBrilinta | $897 | $58,41263 claims |
| Boehringer IngelheimPradaxa | $29 | $2,04511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Phoenix
- Rajkumar SugumaranPhoenix$957K
- Tabitha MoePhoenix$182K
- Jesse SethiPhoenix$150K
- Robert ScottPhoenix$106K
- Kethes WaramPhoenix$66K
- Ayman JamalPhoenix$42K
- Sarika DesaiPhoenix$41K
- Suzanne SorofPhoenix$29K
- Namit RohantPhoenix$25K
- Venkataramanan GangadharanPhoenix$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.